SGCM
AGN

Sand Grove Capital Management’s Allergan Inc AGN Stock Holding History

Sand Grove Capital Management’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-33,400
Closed -$9.16M – 24
2016
Q1 		$9.16M Buy
+33,400
New +$9.16M 5.08% 8

Other funds holding AGN

FIM
Frontier Investment Management Dallas, Texas $1.62B AUM 1.86% 1-Year Est. Return
MCM
Mengis Capital Management Portland, Oregon $658M AUM 39.64% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
HHAA
Henry H. Armstrong Associates Pittsburgh, Pennsylvania $1.03B AUM 4.23% 1-Year Est. Return
DY
Dowling & Yahnke San Diego, California $2.15B AUM 10.82% 1-Year Est. Return
CI
Chartist Inc Seal Beach, California $139M AUM
SIA
Starfire Investment Advisers Southfield, Michigan $209M AUM 2.6% 1-Year Est. Return
CIS
Connors Investor Services Wyomissing, Pennsylvania $1.08B AUM 31.31% 1-Year Est. Return
MA
Marshwinds Advisory St Simons Island, Georgia $187M AUM 1.79% 1-Year Est. Return

Sand Grove Capital Management's AGN Position: Q2 2016 in Review

Sand Grove Capital Management sold out of Allergan Inc (AGN) in Q2 2016, closing a stake of 33,400 shares — an estimated $9.16M sold.

Sand Grove Capital Management first reported a position in AGN in Q1 2016 and held it in 1 quarter. The position peaked at $9.16M in Q1 2016. 13 funds tracked by Wall St. Rank hold AGN as of Q2 2016.

  • Sand Grove Capital Management reported no remaining Allergan Inc position as of Q2 2016 after selling out during the quarter.
  • Sand Grove Capital Management sold 33,400 Allergan Inc shares in Q2 2016, an estimated $9.16M.
  • Sand Grove Capital Management first reported a position in Allergan Inc in Q1 2016 and held it in 1 quarter.
  • Sand Grove Capital Management's Allergan Inc position peaked at $9.16M in Q1 2016.
  • 13 funds tracked by Wall St. Rank held Allergan Inc as of Q2 2016.

Based on Sand Grove Capital Management's 13F filing for Q2 2016, filed 8 Aug 2016.